Navann Ty
Stock Analyst at BNP Paribas
(2.82)
# 1,650
Out of 5,241 analysts
28
Total ratings
64.29%
Success rate
26.02%
Average return
Main Sectors:
Stocks Rated by Navann Ty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Maintains: Neutral | $49 → $40 | $37.70 | +6.10% | 1 | May 14, 2026 | |
| OGN Organon & Co. | Downgrades: Neutral | $12 → $14 | $13.42 | +4.32% | 3 | Apr 29, 2026 | |
| KVUE Kenvue | Initiates: Neutral | $28 | $17.15 | +63.27% | 1 | May 30, 2023 | |
| ALKS Alkermes | Maintains: Neutral | $22 → $26 | $37.00 | -29.73% | 10 | Mar 22, 2022 | |
| VTRS Viatris | Maintains: Neutral | $16 → $11 | $16.17 | -31.97% | 2 | Mar 10, 2022 | |
| ZTS Zoetis | Maintains: Neutral | $184 → $232 | $78.92 | +193.97% | 4 | Dec 20, 2021 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $200 | $237.45 | -15.77% | 7 | Oct 5, 2021 |
Medline
May 14, 2026
Maintains: Neutral
Price Target: $49 → $40
Current: $37.70
Upside: +6.10%
Organon & Co.
Apr 29, 2026
Downgrades: Neutral
Price Target: $12 → $14
Current: $13.42
Upside: +4.32%
Kenvue
May 30, 2023
Initiates: Neutral
Price Target: $28
Current: $17.15
Upside: +63.27%
Alkermes
Mar 22, 2022
Maintains: Neutral
Price Target: $22 → $26
Current: $37.00
Upside: -29.73%
Viatris
Mar 10, 2022
Maintains: Neutral
Price Target: $16 → $11
Current: $16.17
Upside: -31.97%
Zoetis
Dec 20, 2021
Maintains: Neutral
Price Target: $184 → $232
Current: $78.92
Upside: +193.97%
Jazz Pharmaceuticals
Oct 5, 2021
Initiates: Buy
Price Target: $200
Current: $237.45
Upside: -15.77%